Trial Profile

Equivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Nov 2021 Results published in the Journal of Clinical Pharmacology
27 Mar 2020 According to a Rockwell Medical India media release, the U.S. Food and Drug Administration (FDA) has approved New Drug Application (NDA) for its Intravenous (I.V.) formulation of TRIFERIC.
06 Aug 2019 According to a Rockwell Medical Technologies media release, based on the results of this study, the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for its Intravenous (I.V.) formulation of TRIFERIC with a PDUFA (Prescription Drug User Fee Act) date of March 28, 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com